NO20061619L - Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B - Google Patents

Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B

Info

Publication number
NO20061619L
NO20061619L NO20061619A NO20061619A NO20061619L NO 20061619 L NO20061619 L NO 20061619L NO 20061619 A NO20061619 A NO 20061619A NO 20061619 A NO20061619 A NO 20061619A NO 20061619 L NO20061619 L NO 20061619L
Authority
NO
Norway
Prior art keywords
domain
antibody
cdr1
cdr2
seq
Prior art date
Application number
NO20061619A
Other languages
English (en)
Norwegian (no)
Inventor
Barbara Carnemolla
Enrica Balza
Patrizia Castellani
Luciano Zardi
Laura Borsi
Matthias Friebe
Christoph-Stephan Hilger
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of NO20061619L publication Critical patent/NO20061619L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20061619A 2003-09-10 2006-04-10 Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B NO20061619L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50188103P 2003-09-10 2003-09-10
EP03255633A EP1514561A1 (fr) 2003-09-10 2003-09-10 Ciblage de la vasculature tumorale avec l'utilisation de l'anticorps radio-marqué L19 contre le fibronectin ED-B
PCT/EP2004/009733 WO2005023318A1 (fr) 2003-09-10 2004-09-01 Ciblage selectif de systeme vasculaire tumoral au moyen de molecules d'anticorps radiomarquees

Publications (1)

Publication Number Publication Date
NO20061619L true NO20061619L (no) 2006-04-10

Family

ID=34130349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061619A NO20061619L (no) 2003-09-10 2006-04-10 Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B

Country Status (27)

Country Link
US (2) US20050074401A1 (fr)
EP (3) EP1514561A1 (fr)
JP (1) JP2007505065A (fr)
KR (1) KR101129161B1 (fr)
CN (1) CN100482285C (fr)
AT (1) ATE499949T1 (fr)
AU (2) AU2004269897B2 (fr)
BR (1) BRPI0414272A (fr)
CA (1) CA2536256C (fr)
CR (2) CR8331A (fr)
DE (1) DE602004031635D1 (fr)
DK (1) DK1663320T3 (fr)
EA (1) EA010653B1 (fr)
EC (1) ECSP066499A (fr)
ES (1) ES2361743T3 (fr)
IL (1) IL173560A0 (fr)
ME (1) MEP13108A (fr)
NO (1) NO20061619L (fr)
NZ (1) NZ545640A (fr)
PL (1) PL1663320T3 (fr)
PT (1) PT1663320E (fr)
RS (1) RS20060176A (fr)
SG (1) SG162760A1 (fr)
SI (1) SI1663320T1 (fr)
UA (1) UA89759C2 (fr)
WO (1) WO2005023318A1 (fr)
ZA (1) ZA200602014B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
EP2174958A1 (fr) * 2002-03-11 2010-04-14 Philogen S.p.A. Anticorps dérivés de l19 dirigé contre ed-b et le ciblage de la vascularisation tumorale
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
WO2011147762A2 (fr) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Composition radiopharmaceutique stabilisée
CN104395342B (zh) * 2013-06-06 2017-07-04 合肥立方制药股份有限公司 人源抗纤连蛋白ed‑b结构域的抗体及其用途
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US10517238B2 (en) 2017-09-18 2019-12-31 Deere & Company Implement optimization by automated adjustments
WO2020249757A1 (fr) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugués comprenant un dianticorps à chaîne unique et de l'interleukine-15 ou l'interleukine-15 et un domaine sushi du récepteur alpha de l'interleukine-15
JP7352040B2 (ja) 2020-05-22 2023-09-27 フィロジェン エッセ．ピー．アー． 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法
CN111808161A (zh) * 2020-06-01 2020-10-23 北京大学 一种对生物化合物进行放射性标记的方法
JP7690131B2 (ja) 2022-01-04 2025-06-09 フィロジェン ソチエタ ペル アツィオーニ Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
WO2025061801A1 (fr) 2023-09-19 2025-03-27 Philochem Ag Combinaison thérapeutique d'une protéine de fusion il2 ou il12 d'anticorps du domaine de la fibronectine anti-edb et d'un radioconjugué lutétium-177
WO2026003203A1 (fr) 2024-06-27 2026-01-02 Philogen S.P.A. Combinaison d'une immunocytokine comprenant de l'il2 ciblée et d'un inhibiteur de jak
CN119775344B (zh) * 2024-12-31 2025-08-26 英科新创（苏州）生物科技有限公司 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
WO2001096599A2 (fr) * 2000-06-15 2001-12-20 Philogen S.R.L. Procedes de determination quantitative de b-fibronectine dans des fluides et des tissus biologiques
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
EP2174958A1 (fr) * 2002-03-11 2010-04-14 Philogen S.p.A. Anticorps dérivés de l19 dirigé contre ed-b et le ciblage de la vascularisation tumorale

Also Published As

Publication number Publication date
HK1092375A1 (zh) 2007-02-09
NZ545640A (en) 2009-05-31
ZA200602014B (en) 2007-05-30
US20050074401A1 (en) 2005-04-07
CR20110168A (es) 2011-06-03
SG162760A1 (en) 2010-07-29
WO2005023318A1 (fr) 2005-03-17
US20090214423A1 (en) 2009-08-27
MEP13108A (en) 2011-05-10
IL173560A0 (en) 2006-07-05
AU2010200271A1 (en) 2010-02-18
EA010653B1 (ru) 2008-10-30
PL1663320T3 (pl) 2011-07-29
DK1663320T3 (da) 2011-06-06
EP1663320B1 (fr) 2011-03-02
CA2536256C (fr) 2013-02-26
UA89759C2 (ru) 2010-03-10
CR8331A (es) 2006-10-04
ECSP066499A (es) 2006-10-10
CN1849144A (zh) 2006-10-18
AU2004269897B2 (en) 2009-11-05
CA2536256A1 (fr) 2005-03-17
EA200600494A1 (ru) 2006-08-25
EP2246070A2 (fr) 2010-11-03
DE602004031635D1 (de) 2011-04-14
JP2007505065A (ja) 2007-03-08
CN100482285C (zh) 2009-04-29
ATE499949T1 (de) 2011-03-15
RS20060176A (sr) 2008-08-07
KR101129161B1 (ko) 2012-03-28
EP1663320A1 (fr) 2006-06-07
AU2004269897A1 (en) 2005-03-17
ES2361743T3 (es) 2011-06-21
SI1663320T1 (sl) 2011-06-30
EP1514561A1 (fr) 2005-03-16
BRPI0414272A (pt) 2006-11-07
KR20060118430A (ko) 2006-11-23
PT1663320E (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
CR20110168A (es) Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-b de fibronectina marcado radioactivamente (divisional solicitud 8331)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
WO2007062245A3 (fr) Anticorps monoclonal humain cd134 (ox40) et procedes de fabrication et d'utilisation de celui-ci
PE20020871A1 (es) Moleculas de enlace terapeuticas
HRP20110758T1 (en) Il-17 antagonistic antibodies
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
WO2006089133A8 (fr) Anticorps anti-cd19 et leur utilisation en oncologie
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2006133450A3 (fr) Therapie a anticorps diriges contre cd19 a des fins de transplantation
WO2006121852A3 (fr) Traitements des maladies auto-immunes par anticorps anti-cd19
NO20026063D0 (no) Antistoffer mot human MCP-1
WO2005112564A3 (fr) Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation
WO2006055809A3 (fr) Anticorps contre le recepteur 1 du facteur de croissance endotheliale vasculaire
BRPI0414515A (pt) moléculas de ligação terapêuticas
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
WO2000074729A3 (fr) Palmes pour la nage de la brasse
WO2005010153A3 (fr) Anticorps et utilisations de ceux-ci
JP2007508352A5 (fr)
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application